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R. Duquesnoy, and M. Griffin 
T HE GUIDELINES for solid organ trans-plantation from donors to recipients of 
different blood types were established by 
observations in a relatively small number of 
renal transplantations carried out in 1962 and 
1963. 1•3 In this presentation. we will retrace 
these steps, suggest how lessons with ABO 
mismatches are applicable to other preformed 
antibody states (including those of xenotrans-
plantation). and show how modern day 
strategies with antibody depletion and phar-
macologic manipulation of mediators of the 
inflammatory response could be exploited 
therapeutically to prevent hyperacute rejec-
tion. 
HYPERACUTE REJECTION 
Kidney Transplantation 
The first experience was reassuring. On 
January 31, 1963, a 38-year-old man of A + 
blood type was given a kidney from his sister 
whose blood type was B +. Despite a moder-
ately severe rejection at 25 days, the kidney 
survived and still functions perfectly more 
than 24 years later. On March 19 and July 29 
of the same year, two A to 0 transplantations 
were performed, one from a cadaveric donor 
and the other from a mother. also without 
perioperative incident. 
It looked as if ABO matching was irrele-
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vant in renal transplantation and a manu-
script with this conclusion was accepted by 
Surgen'.' While the article was still in press 
its message was changed drastically by tw~ 
catastrophic experiences. one with an A to 0 
transplantation and the other witr a B \0 0 
transfer. Both kidneys were hyperacutel} 
rejected within minutes. 
Arteriograms of the removed specimen 
showed nonfilling of the small vessels and this 
correlated histopathologically with wide-
spread throm botic occlusion of the microvas-
culature. It was concluded that the immediate 
rejection had been precipitated by high affin-
ity isoagglutinins in the recipient sera. which 
had bound with A or B antigens in the mis-
matched kidneys. The logic of the conclusion 
was supported by the documentation 2 or 3 
years earlier by pzulman~ and by Hogman 5 
that the ABO antigens were widely distrib-
uted throughout human tissues and organs. 
An addendum was added to the Surgery 
article including the now familiar table show-
ing permissible patterns of tissue transfer that 
were designed to a void placing kidneys into an 
environment containing antigraft isoaggluti-
nins (Table 1). Data on isoagglutinin titers 
was subsequently provided.] Later. in a classi-
cal report. Rapaport et al" showed how sensiti-
zation of human volunteers with purined A or 
B antigens caused increased titers of isoagglu-
tinins and accelerated (white graft) rejection 
of subsequent"!y transplanted skin grafts. The 
circle of evidence seemingly was complete. 
However. it is worth emphasizing that not all 
of the mismatched kidneys had rejected and 
that those that escaped immediate destruction 
did not seem to pay a later penalty. 
Much of the recent interest in the ABO 
system by transplanters has been focused on 
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HUMORAL ANTIBODY STATES 
Table 1. Direction of Acceptable Mismatched 
Tissue Transter 
o to non-0 
Rh - '0 Rh.;.. 
Rh-'- to Rh-
A to non-A 
B to non-B 
AS to non-AB 
Safe 
Safe 
Relatively Safe 
Dangerous 
Dangerous 
Dangerous 
NOTE. 0 is universal donor: AS IS universal recipient. 
reliably surmounting the acute antibody bar-
rier. thereby expanding the available pool of 
organs. The recent use of Az kidneys for 0 
recipients is an example. The practice is based 
on the reports by Breimer and Brynger et a1 7.8 
of Sweden who showed that the A antigen is 
poorly represented in the kidneys of nonsecre-
tor individuals or in patients with A2 blood 
type, The assumption has been that kidneys 
from such donors would not be the target of 
the anti-A isoagglutinins in 0 or B recipients. 
However, this newest attempt to ride over 
an ABO barrier may not be completely safe. 
On December 28, 1986 in Pittsburgh, a 39-
year-old male of 0 blood type was given a 
kidney from an A2 cadaveric donor. Cold 
ischemia time was 351/2 hours. The kidney 
underwent hyperacute rejection within five 
minutes. The anti-A isoagglutinin titers are 
summarized in Table 2. The anti-A, titers of 
both IgG and [gM were high by co~parison 
with those in other candidates for kidnevs. 
livers. or hearts (Table 3). -
Histopathologic examinations showed the 
same lesions as in the hyperacutely rejected 
ABO incompatible kidney 25 years previously 
lFig I), IgM and complement were found in 
the vessel walls (Fig I). Fortunately, an 0 
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Table 2. Isoagglutinin Titers Before and After 
Hyperacute Rejection of a Kidney From an A, 
Nonsecretor Donor to an 0 Recipient 
Antt- Before After 
A, IgM 128 64 
IgG >512 512 
A2 IgM 128 128 
IgG 1,024 512 
B IgM 256 64 
IgG 512 256 
kidney became available while the wound was 
still open and it was inserted with a perfect 
result. 
Extrarenal Organs 
How much relevance the guidelines sum-
marized in Table I will have to do with other 
organs is still being determined. For many 
years, it has been appreciated that the liver is 
resistant to hyperacute rejection.9 Today 
reports will be given from three different 
centers about what the risks and probabilities 
actually are in using ABO incompatible liv-
ers. 
There have been a few accidental heart 
transplantations across ABO barriers. In 
Pittsburgh, there have been two such cases. 
One recipient has a perfect result after 18 
months, but the other died in less than a day 
with accelerated rejection (Table 4). 
To leave this underdeveloped subject, our 
opinion is that there is a small but real 
jeopardy in crossing these forbidden ABO 
barriers in heart and liver recipients unless 
some specific provisions such as depletion of 
isoagglutinins or pharmacologic therapy is 
carried out as we will mention later. 
Table 3. Isohemagglutinin Titers in Group a liver, Heert, or Renal Transplant Candidetes 
Anti-A, In - 53! Ant,-A, In - 24) Anti-S In - 521 
IgM IgG IgM IgG IgM IgG 
-------------------------------------------------------------------------------
Median 128 256 J2 64 128 256 
~ected range" 32-256 64-1,024 s 16-256 s 16-512 s 16-256 s 16-1,024 
NOTE. IgM, 60-mlnute room temperature saline incubation; IgG, 60-minute 37"C salme 'ncubation, then anti-lgG 
antiglObulin. 
*90% of patients are In these ranges. 
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Fig 1: (AI Glomerulus with congested capillary loops. which contain platelet-fibrin thromb, and many 
neutrophils (hemotoxylin-eosin: origlnai magnification" 4001. {BJ Immunofluorescent stain for anti-Igm (o"ginal 
magnIficatIon, 4001 with dense deposition of IgM in polar arteriole. 
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HUMORAL ANTIBODY STATES 
Table 4. Hearl Transplants Across ABO Barrier 
IPittsburgh) 
ABO 
Case Donor ReClp!em Outcome 
!l,B A Good. 18 mo 
2 A 0 Died of ,ejection 12 h 
HYPERACUTE REJECTION WITH NON-ABO 
ANTIBODIES 
It was not long after the description of 
hyperacute renal rejection with ABO mis-
matches that a similar phenomenon was 
described by Terasaki in a patient with anti-
graft preformed Iymphocytotoxic antibod-
ies. lo The concept that immediate graft rejec-
tion could be caused by preformed antibodies 
was confirmed and extended by Kissmeyer 
Neilsen,II Patel and Terasaki,I2 Williams et 
aI, IJ and many others. Other systems, such as 
the anti-vascular endothelial cell antibodies 
discussed by Cerilli elsewhere in this sympo-
sium, appears to precipitate the same kind of 
hyperacute rejection of various organs. l4 
Thus, the initiating antibodies or other cir-
cumstances have differed. but a final common 
pathway of destruction has been involved in 
all. 
THE EFFECTOR CASCADE 
About 20 years ago, we made serious 
~ttempts to delineate that common pathway 
In a series of inquiries in patients and animals 
t?at were strongly intluenced by collabora-
tIOns with the experimental pathologist, Frank 
J. Dixon of La Jolla, CA and the immunolo-
gist, Paul 1. Terasaki. I5.2l Two experimental 
models were used. One was the dog that was 
hypersensitized with multiple surface or 
buried skin grafts.Io.zo.::1 Kidney, liver, or 
spleen transplantation from the sensitizing 
donor was then performed. The other experi-
mental model was the pig to dog xeno-
graft. 18 ,19.21 The dog had preformed hetero-
specific cytotoxic antibodies that led to 
hyperacute rejection of the pig kidney within 
5 to 30 minutes. IS 
4495 
In addition, an opportunity presented to 
observe the events of hyperacute rejection in a 
small number of hypersensitized human kid-
ney recipients. !S.i7 From these observations 
the hypothesis was developed that the initiat-
ing step of hyperacute rejection was antibody 
induced. but that the irreversible injury pat-
terns resulted from a cascade of secondary 
and nonspecific events. It was shown that 
antibodies, clotting factors, and formed blood 
elements were rapidly cleared by the grafts as 
estimated by gradient measurements.I6-i8.20 
Fibrinolysis from the renal vein also was a 
consistent finding, and in extreme cases, a 
disseminated intravascular coagulation (DIC) 
could be produced. I6 .!7 
Va rious descriptive terms have been 
applied to hyperacute rejection and its dif-
ferent aspects have been emphasized by com-
parison to the Arthus reaction,13 inverse ana-
phylaxis, lJ and the generalized Swartzman 
reaction. IS Each of these classic immunologic 
phenomena is, or can be, initiated by interac-
tion of antibody and antigen, and in each there 
are multiple secondary events including 
inflammation and coagulation. It was our 
conclusion that hyperacute rejection was "an 
immunologically mediated coagulopathy that 
led to the devascularization and destruction of 
a transplanted organ. and which sometimes 
resulted in systemic coagulation abnormali-
ties."I) 
At the time this work was going on, there 
was little detailed information about the 
mediators of the inflammatory response. The 
modern understanding of the inflammatory 
response following a variety of initiating 
events including antigen-antibody reactions is 
summarized by Makowka elsewhere 10 this 
symposium. 
THERAPEUTIC INTERVENTION FOR 
HYPERACUTE REJECTION 
Antibody Removal 
Almost two decldes ago, therapeutic 
efforts to treat preformed antibody states 
were made in spite of the above described lack 
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of knowledge. The most obvious approach was 
to eliminate the offending antibodies. The 
first attempt to our knowledge was made by 
Merkel and Bier et a1. 19•22 Using a primitive 
plasmapheresis machine, it was possible to 
extend many times the life of the pig to dog 
renal xenografts. A number of clinical trials of 
plasmapheresis to reduce antibodies have 
been reported through the years but with 
unpredictable and often uninterpretable re-
sults. Plasmapheresis has been used by the 
group at the Catholic University of Louvain 
for reduction of isoagglutinin titers before 
transplantation across ABO barriers (sum-
mary report elsewhere in this volume). 
Thoracic duct drainage is an alternative 
technique to reduce antibodies. Even though 
thoracic duct drainage removes T-Iympho-
cytes, which are not known to effect antibody 
function, there is an accompanying drastic 
reduction by unexplained mechanisms of all of 
the immunoglobulin ciasses.23.24 Machleder 
and Paulus23 showed that isoagglutinins could 
be virtually eliminated with 3 or 4 weeks of 
thoracic duct drainage. 
Antibody reduction by any currently avail-
able techniques is of limited value and dura-
tion, but technologic developments with the 
so-called staphylococcal protein A adsorbent 
columns25 will make it possible within the next 
year or so to virtually remove specific classes 
of immunoglobulins for long periods of time 
peri opera livel y. 
Altering (he Effector Cascade 
When it was first appreciated that the 
effector cascade of hyperacute rejection was a 
relatively nonspecific one involving coagula-
tion. the simple expedient of using heparin for 
anticoagulation was tried. but with no bene-
fit. 26 Other means to prevent coagulation or 
complement activation have included the use 
of snake venom in experimental animals. 
Research of this kind came to an abrupt 
standstill almost 15 years ago because of the 
great difficulty in achieving anything of prac-
tical therapeutic value. The most successful 
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technique with either the difficult pig to dog 
model or after sensitization with skin homo_ 
grafts was the intraarterial infusion of 
citrate.21 Citrate in toxic doses can be a pro-
found anticoagulant but it has so many other 
biologic effects including participation in 
complement activation that the specificity of 
action could not be clarified. 
With the development of new drugs with 
which one can intervene at specific levels of 
the inflammatory response, the prospect of 
mitigating or preventing hyperacute rejection 
has become more practical, as will be dis-
cussed by Leonard Makowka later this mOrn-
ing. The work that Dr Makowka will report 
should be directly applicable to the ABO 
questions central to this meeting. 
GRAFT -VERSUS-HOST CONSIDERATIONS 
So far, we have discussed only how pre-
formed recipient antibodies can damage ABO 
mismatched grafts. It has become well recog-
nized that grafts containing lymphoid tissue 
can act as B cell organs and elaborate isoag-
glutinins or other antibodies that can bind 
with host tissues. In one of our A recipients 
who was given an 0 pancreatico duodenal-
splenic graft, the spleen produced such high 
titers of anti A isoagglutinins that a hemolytic 
crisis was caused. 27 Livers predictably cause 
hemolysis under similar circumstances28 but 
less severely. Other syndromes such as throm-
bocytopenia may result. The possibility of this 
kind of humoral graft-versus-host reaction 
exists even-with the kidneyK~9 Such observa-
tions have made it less and less desirable to 
perform transplantation from universal do-
nors and with,Dther so-called compatible but 
not identical combinations. especially with 
nomenal organs. 
SUMMARY 
The first examples of hyperacute rejection 
of rena! hemografts were seen almost 25 years 
ago when kidneys were transplanted to ABO 
incompatible recipients whose plasma con-
tained antigraft isoagglutinins. Hyperacute 
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HUMORAL ANTiBODY STATES 
rejection caused in sensitized recIpIents bv 
lymphocytotoxic antibodies is similar in that 
the immune reaction triggers an acute inflam-
matory reaction that leads to widespread 
thrombotic occlusion and devascularization of 
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the graft. The events after xenotransplanta-
tion between certain species are essentially the 
same. Potential strategies to avoid the precipi-
tating antigen antibody reaction or to mitigate 
the resulting effector cascade are described. 
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